Yeramian Patrick D
Known title: Chief Medical OfficerCIK: 0001358266
Associated companies
Transaction History
| AMLX | ▼ Sell | Open Market | 2,812 | $46K | 1/9/2024 | View on chart |
| AMLX | ▲ Buy | Option Exercise | 2,201 | $814 | 5/15/2023 | View on chart |
| AMLX | ▲ Buy | Option Exercise | 9,764 | $67K | 5/15/2023 | View on chart |
| AMLX | ▼ Sell | Open Market | 11,965 | $347K | 5/15/2023 | View on chart |
| AMLX | ▲ Buy | Option Exercise | 44,861 | $17K | 4/17/2023 | View on chart |
| AMLX | ▲ Buy | Option Exercise | 4,718 | $32K | 4/17/2023 | View on chart |
| AMLX | ▼ Sell | Open Market | 49,279 | $1.5M | 4/17/2023 | View on chart |
| AMLX | ▼ Sell | Open Market | 300 | $9K | 4/17/2023 | View on chart |
| AMLX | ▼ Sell | Open Market | 52,211 | $1.7M | 3/16/2023 | View on chart |
| AMLX | ▼ Sell | Open Market | 2,416 | $78K | 3/16/2023 | View on chart |
| AMLX | ▲ Buy | Grant | 9,167 | $0 | 3/16/2023 | View on chart |
| AMLX | ▼ Sell | Open Market | 1,405 | $51K | 1/6/2023 | View on chart |
| AMLX | ▼ Sell | Open Market | 629 | $23K | 1/6/2023 | View on chart |
| AMLX | ▲ Buy | Grant | 28,333 | $0 | 1/6/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Amylyx to Present Phase 3 Avexitide Data at ObesityWeek 2026
Amylyx Pharmaceuticals is scheduled to present topline data from its Phase 3 LUCIDITY trial for avexitide at the ObesityWeek 2026 annual meeting. The data will focus on the drug's efficacy and safety in treating post-bariatric hypoglycemia. This upcoming presentation is a key catalyst for the company, as it provides new clinical evidence for a major therapeutic area.
Amylyx to Present Phase 3 Avexitide Data at ObesityWeek 2026. Amylyx Pharmaceuticals is scheduled to present topline data from its Phase 3 LUCIDITY trial for avexitide at the ObesityWeek 2026 annual meeting. The data will focus on the drug's efficacy and safety in treating post-bariatric hypoglycemia. This upcoming presentation is a key catalyst for the company, as it provides new clinical evidence for a major therapeutic area.